Scarica l'app Stockscreener
10.51
2.84%
0.29
Dopo l'orario di chiusura:
10.50
-0.010
-0.10%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ATRA Giù?
Forum
Previsione
Precedente Chiudi:
$10.22
Aprire:
$10.2
Volume 24 ore:
45,295
Relative Volume:
0.03
Capitalizzazione di mercato:
$94.70M
Reddito:
$23.14M
Utile/perdita netta:
$-9.47M
Rapporto P/E:
-11.91
EPS:
-0.8827
Flusso di cassa netto:
$-25.88M
1 W Prestazione:
+4.37%
1M Prestazione:
+9.37%
6M Prestazione:
-39.14%
1 anno Prestazione:
+32.20%
Intervallo 1D:
$10.15
$10.71
Intervallo di 1 settimana:
$9.66
$11.55
Portata 52W:
$3.92
$19.14
Atara Biotherapeutics Inc Stock (ATRA) Company Profile
Nome
Atara Biotherapeutics Inc
Settore
Industria
Telefono
805-623-4211
Indirizzo
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
Compare ATRA vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ATRA
Atara Biotherapeutics Inc
|
10.51 | 92.08M | 23.14M | -9.47M | -25.88M | -0.8827 |
VRTX
Vertex Pharmaceuticals Inc
|
491.34 | 121.87B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
632.90 | 65.01B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
887.18 | 55.26B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.37 | 39.14B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
182.08 | 37.88B | 742.00K | -1.37B | -1.07B | -7.0731 |
Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-13 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-11-09 | Downgrade | Evercore ISI | Outperform → In-line |
| 2023-11-09 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-11-09 | Downgrade | Mizuho | Buy → Neutral |
| 2022-07-20 | Downgrade | Citigroup | Neutral → Sell |
| 2022-07-13 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-07-13 | Downgrade | Stifel | Buy → Hold |
| 2022-05-10 | Downgrade | Citigroup | Buy → Neutral |
| 2021-05-13 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-12-09 | Downgrade | Citigroup | Buy → Neutral |
| 2020-12-08 | Reiterato | H.C. Wainwright | Buy |
| 2020-11-10 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-30 | Iniziato | Evercore ISI | Outperform |
| 2020-06-15 | Iniziato | H.C. Wainwright | Buy |
| 2020-04-23 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-11-08 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-09-27 | Downgrade | Goldman | Neutral → Sell |
| 2019-09-16 | Downgrade | Jefferies | Buy → Hold |
| 2019-06-04 | Aggiornamento | Citigroup | Sell → Neutral |
| 2019-05-30 | Iniziato | ROTH Capital | Buy |
| 2019-05-23 | Iniziato | Stifel | Buy |
| 2019-01-23 | Iniziato | Mizuho | Buy |
| 2018-04-10 | Iniziato | JP Morgan | Overweight |
| 2018-03-16 | Iniziato | Guggenheim | Neutral |
| 2018-03-05 | Reiterato | Jefferies | Buy |
| 2018-02-28 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-02-15 | Downgrade | Citigroup | Neutral → Sell |
| 2018-01-03 | Aggiornamento | Citigroup | Sell → Neutral |
| 2017-10-06 | Ripresa | Goldman | Neutral |
Mostra tutto
Atara Biotherapeutics Inc Borsa (ATRA) Ultime notizie
Atara Biotherapeutics (NASDAQ: ATRA) appoints CRCFO consultant as interim CFO - Stock Titan
Atara Biotherapeutics Inc Actuals & Estimates (NASDAQ:ATRA) - TradingView
ATRA Forecast — Price Target — Prediction for 2027 - TradingView
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Atara Biotherapeutics Inc (ATRA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Atara Biotherapeutics Inc (ATRA) Institutional Confidence - TradingKey
Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Behavioral Patterns of ATRA and Institutional Flows - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Shareholders to Connect - ACCESS Newswire
ATRA News | ATARA BIOTHERAPEUTICS INC (NASDAQ:ATRA) - ChartMill
Atara Biotherapeutics Inc (ATRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Atara Biotherapeutics Inc (ATRA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Atara Biotherapeutics Inc (ATRA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Atara Biotherapeutics Inc (ATRA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Atara Biotherapeutics Inc (ATRA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Atara Biotherapeutics Inc (ATRA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Atara Biotherapeutics Inc (ATRA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Connect - ACCESS Newswire
Atara Biotherapeutics | 4: Statement of changes in beneficial ownership of securities-Director Cherry Brian N - Moomoo
Atara Biotherapeutics (ATRA) director awarded 24,000 restricted stock units - Stock Titan
Atara Biotherapeutics (NASDAQ: ATRA) director reports 38,320-share common stock holding - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Atara Biotherapeutics Adds Independent Director to Board - The Globe and Mail
Atara Biotherapeutics appoints Brian Cherry to board By Investing.com - Investing.com Australia
Atara Biotherapeutics appoints Brian Cherry to board - Investing.com
New Atara (NASDAQ: ATRA) director and 2026 shareholder vote outcomes - Stock Titan
Atara Biotherapeutics Announces Changes to Its Board of Directors - The Joplin Globe
symbol__ Stock Quote Price and Forecast - CNN
Atara Biotherapeutics (ATRA) director granted 12,000 restricted stock units - Stock Titan
Atara Biotherapeutics | 4: Statement of changes in beneficial ownership of securities-Director Fust Matthew K - Moomoo
Atara Biotherapeutics (ATRA) director receives 12,000-share RSU grant - Stock Titan
Atara Biotherapeutics (ATRA) awards director 12,000 RSUs and reports fund holdings - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
ATRA: All proposals, including director elections and equity plan amendment, were approved - TradingView
Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Atara Biotherapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
2026-06-09 | Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:ATRA | Press Release - Stockhouse
(ATRA) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
2026-06-07 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Connect | NDAQ:ATRA | Press Release - Stockhouse
ATRA stock shoots up 82% in a month: Here's what you should know - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
2026-06-04 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Stockholders to Learn More About the Investigation | NDAQ:ATRA | Press Release - Stockhouse
Atara Biotherapeutics, Inc. Common Stock (ATRA) Stock Price Today & Analysis - Gotrade
Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Investors to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeuti - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Reach Out - ACCESS Newswire
2026-05-31 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Reach Out | NDAQ:ATRA | Press Release - Stockhouse
Atara Biotherapeutics (ATRA) Drops Over 6% as Stock Nears Critical Support LevelVolatility Smirk - Město Břeclav
How (ATRA) Movements Inform Risk Allocation Models - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Reach Out - ACCESS Newswire
Atara Biotherapeutics Inc Azioni (ATRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.36%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):